EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years

Sara Y Tartof, Tara Ahi, Timothy B Frankland, Jeff M Slezak iD, Joann M Zamparo, Bradley K Ackerson, Laura Puzniak

Journal of the Pediatric Infectious Diseases Society · 20.05.2026 · 15 (5)

DOI: 10.1093/jpids/piag029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 03.04.2026. Verfasst von Sara Y Tartof und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Southern California Department of Research & Evaluation, Division of Epidemiology, Pasadena, CA, United States. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, Vaccine Efficacy, COVID-19 Vaccines. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a test-negative case–control design among children aged 6 months-4 years (n = 11 878) and 5-17 years (n = 16 687) in Kaiser Permanente Southern California, BNT162b2 2024-2025 effectiveness against hospitalization/emergency department/urgent care/outpatient was 36% (95% CI, -5% to 61%) and 42% (-2% to 67%), respectively suggesting pediatric COVID-19 vaccination remains beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19Vaccine EfficacyCOVID-19 VaccinesHumansInfantChild, PreschoolAdolescentChildMaleSARS-CoV-2FemaleCase-Control StudiesCaliforniaHospitalizationVaccination

Stichwörter der Autor:innen

BNT162b2COVID-19KP.2pediatricvaccine effectiveness

Substanzen

BNT162 VaccineCOVID-19 Vaccines

Autor:innen und Institutionen

  • Kaiser Permanente Southern California Department of Research & Evaluation, Division of Epidemiology, Pasadena, CA, United States.
  • Pfizer Inc., Global Vaccines Real World Evidence, New York, NY, United States.
  • Kaiser Permanente Hawaii Center for Integrated Health Care Research, Data Reporting and Analytics, Honolulu, HI, United States.
  • Southern California Permanente Medical Group, Pediatric Infectious Diseases, Harbor City, CA, United States.

ORCID-Profile: Jeff M Slezak

Förderung

  • Pfizer Inc.

Zitieren

APA

Tartof, S. Y., Ahi, T., Frankland, T. B., Slezak, J. M., Zamparo, J. M., Ackerson, B. K., & Puzniak, L. (2026). BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years. Journal of the Pediatric Infectious Diseases Society, 15(5). https://doi.org/10.1093/jpids/piag029

Vancouver

Tartof SY, Ahi T, Frankland TB, Slezak JM, Zamparo JM, Ackerson BK, et al. BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years. Journal of the Pediatric Infectious Diseases Society. 2026;15(5). doi:10.1093/jpids/piag029

BibTeX
@article{Tartof2026,
  author = {Tartof, Sara Y and Ahi, Tara and Frankland, Timothy B and Slezak, Jeff M and Zamparo, Joann M and Ackerson, Bradley K and Puzniak, Laura},
  title = {BNT162b2 2024-2025 Vaccine Effectiveness Against COVID-19 in Children Aged 6 Months-17 Years},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1093/jpids/piag029}
}
Kostenlos starten →